180384-56-9

180384-56-9 structure

Name: N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-methyl-pyridine-2-sulfonamide
Chemical Name: N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-methylpyridine-2-sulfonamide
CAS Number: 180384-56-9
Molecular Formula: C₂₅H₂₃N₉O₆S
Molecular Weight: 577.57200
Catalog: Signaling Pathways GPCR/G Protein Endothelin Receptor
Create Date: 2018-05-15 08:00:00
Modify Date: 2025-08-24 18:47:21
Clazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction[1][5].

Name	N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-methylpyridine-2-sulfonamide
Synonyms	UNII-3DRR0X4728 Clazosentan

Description	Clazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction[1][5].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> Endothelin Receptor
In Vitro	Clazosentan (0.1 μM) inhibits the ETA receptor in cerebral arteries[3]. Clazosentan is a substrate of the organic anion-transporting polypeptide (OATP) 1B1/1B3[5].
In Vivo	Clazosentan (10 μM, 0.05 mL/kg, intracisternal injection) inhibits the contractile responses to ET-1 in rats[2]. Clazosentan (10 mg/kg, s.c.) inhibits IL-33-induced hypernociception in mice[4]. Animal Model: Rats[2] Dosage: 10 μM, 0.05 mL/kg Administration: Intracisternal injection Result: Inhibited the contractile responses to ET-1, without preventing SAH-induced upregulation of ET receptors in cerebral arteries.